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Abstract. 
Background: The protein Glypican-3 has been found in various types of tumors and has 
shown promise as a tumor marker. However, there is still very limited information about the 
role of Glypican-3 in breast cancer. Tissue microarray (TMA) analyzes thousands of speci-
mens in parallel with minimal damage to the origin blocks. The purpose of this study was to 
ascertain the role of Glypican-3 status in breast cancer using TMA. 
Materials and Methods: Archival tissue specimens from 99 patients with primary invasive 
breast cancer were analyzed for Glypican-3 expression by immunohistochemical staining with 
TMA. The results were compared to clinicopathologic data by the use of multivariate analysis. 
Results: TNM stage was significantly related to the overall 5-year survival rate. Nevertheless, 
Glypican-3 expression has no significant relationship to overall five-year survival. 
Conclusions: Immunohistochemical staining with TMA was convenient and feasible for ana-
lyzing Glypican-3 expression status in breast cancer. However, our preliminary results show 
that Glypican-3 expression had no significant prognostic value in breast cancer. 
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中文摘要 
前言：Glypican-3 已經在不同類型的腫瘤中被發現。然而，關於 Glypican-3 在乳癌的角色
的資訊仍然非常有限。組織微陣列使用對原始組織標本最小損害的平行原點塊來分析數
以千計的標本。本研究將使用組織微陣列檢測乳癌中的 Glypican-3 之表現。 
材料方法：以組織微陣列的組織免疫染色來分析 99 個原發浸潤性乳腺癌案例的組織檢體
的 Glypican-3 之表現。結果將與臨床病理資料多元分析及比較。 
結果：TNM 分期顯著與 5 年內的生存率相關。不過，Glypican-3 的表現與 5 年內的生存
率沒有明顯的關係。 
結論：組織微陣列的組織免疫染色是方便及適合用於分析乳癌中的 Glypican-3。我們的初
步結果顯示，Glypican-3 的表現在乳腺癌無顯著預後價值。 
 
關鍵字: glypican-3、乳癌、組織微陣列 
 
INTRODUCTION 
Breast cancer is a complex disease entity with dif-
ferent biological characteristics and clinical behaviors 
[1-3]. A variety of clinical features, pathological find-
ings and genetic variants have been identified and 
characterized for the prediction of responses to treat-
ment and outcomes in patients with breast cancer 
[3,4]. 
Glypican-3(GPC3) is a heparin sulfate proteogly-
can that attaches to the exocytoplasmic surface of  
the plasma membrane through a covalent glycosyl- 
phosphatidylinositol (GPI) anchor [5]. GPC3 is in-
volved in the migration, proliferation and modulation 
of cell survival in a variety of tissues [6-8]. Downreg-
ulation of GPC3 expression has been reported in sev-
eral human neoplasms [9,10]. 
The creation of tissue microarrays (TMA) allows 
for the rapid immunohistochemical analysis of thou-
sands of tissue samples while causing minimal dam-
age to the original blocks [11,12]. 
This study was designed to evaluate the use of 
TMA for analyzing the GPC3 expression in breast 
cancer and to explore its potential in the management 
of breast cancer. 
 
MATERIALS AND METHODS 
 
Specimen Selection and Data Collection 
Archival tissue specimens from 99 patients with 
primary invasive breast cancer were selected from 
pathology files at Kaohsiung Chang Gung Memorial 
Hospital between January 1994 and December 1998. 
Among the study participants, all patients had under-
gone modified radical mastectomy due to invasive 
breast cancer. For purpose of this investigation, inva-
sive breast cancer is defined as carcinoma with inva-
sion to or beyond the basement membrane regardless 
of histological classification (ductal or lobular) [13]. 
Data regarding primary tumor staging, age, estrogen 
receptor status [14-16], lymph node status, histologi-
cal grading and TNM staging were also collected. 
Thereafter, hematoxylin-eosin-stained slides of 
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Figure 1. Representative breast cancer cases with 
immunostaining. The score 3 case shows 
diffuse and strong nuclear and cytoplasmic 
expression of Glypican-3 in the tumor 
cells. Original magnification, 200x 
 
 
paraffin-embedded tumor specimens were reviewed 
by our pathologists to confirm the accuracy of the 
histological diagnoses and lymph node status. 
 
TMA Assembly 
Representative areas of both the tumor and 
non-tumorous tissues from each case were selected 
and circled to match the blocks for the TMA. Blocks 
matching the circled slides were retrieved and pre-
pared for the microarray. Three areas each for both 
tumor and non-tumorous parts per case were used for 
assembling the recipient blocks. Each target area on 
the selected blocks was punched to form a 0.6-mm- 
diameter tissue core and placed consecutively on the 
recipient blocks of approximately 3 cm X 2 cm with a 
precision instrument (Beecher Instruments, Silver 
Spring, MD, USA) as described elsewhere [17]. 
 
Immunohistochemical Analysis 
Rabbit Anti-Human Glypican-3 monoclonal anti-
body (Clone SP86), SPRING BIOSCIENCE, 
Pleasanton, CA, USA) was diluted 1:400 in phos-
phate-buffered saline (PBS). Five-micrometer sections 
were cut from the recipient blocks of the tissue micro-
array, incubated overnight in a 37°C oven, dewaxed in 
xylene, and dehydrated in a series of graded alcohols. 
The sections were then treated with 3% hydrogen 
peroxide for 10 minutes to exhaust the endogenous 
peroxidase activity and then microwaved in 10 mM 
citrate buffer pH 6.0 to unmask the epitopes. After 
antigen retrieval was completed, the sections were 
incubated with diluted Glypican-3 antibody for 1 hour 
followed by PBS wash. Horseradish peroxidase (HRP) 
/Fab polymer conjugate (Ultra Tek HRP anti-polyvalent 
kit; Scy-Tek, Logan, Utah, USA) was then applied to 
the sections for 30 minutes. After washing, the sec-
tions were incubated with peroxidase substrate dia-
minobenzidine for 5 minutes and counterstained with 
hematoxylin. 
 
Grading for Glypican-3 Immunostaining 
The immunoreactivity of Glypican-3 was scored 
using a three-tier method: a score of 1 indicated no or 
faint staining in tumor cells; a 2 indicated moderate 
staining in tumor cells; and a score of 3 indicated 
strong staining in tumor cells (Figure 1). The Glypi-
can-3 expression was present in both the nucleus and 
the cytoplasm by immunostaining. 
 
Patients and Follow-Up 
All of the patients were women from 26 to 76 
years old, with a mean age of 49±10.6 years. The 
mean follow-up was 67.9±27.4 months (range, 5 to 98 
months). Follow-up was usually performed every 
three months for the first two years and then every six 
months for the next three years. After five years, fol-
low-up was done on an annual basis. Chest radiog-
raphy, serum alkaline phosphatase level, and detailed 
physical examination were usually performed at fol-
low-up. Annual mammography or breast sonography 
(for the younger patients) were performed. Radionu-
clide bone scan, abdominal sonography or other image 
studies were performed if specific symptoms, signs or 
elevated serum alkaline phosphatase level were noted. 
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Data regarding patient survival, clinical status, and 
clinicopathologic factors were also obtained either 
from patient medical records or through contact with 
the patients at the outpatients clinics or by telephone, 
or both. 
 
Statistical Analyses 
Comparisons between groups were performed us-
ing either the Fisher’s test or Chi- squared test, 
whichever was appropriate. For survival analyses, the 
end-point was overall survival, and survival differ-
ences were compared using the log-rank test. To as-
sess the relative influence of the potential prognostic 
variables on survival, all clinicopathological and ge-
netic variables were entered into the final Cox’s pro-
portional hazards model for multivariate analysis. Sta-
tistical analyses were conducted using SPSS software 
(version 17.0; SPSS, Chicago, IL, USA). Statistical 
significance was set at p < 0.05. All p-values were 
estimated from two-sided tests. 
Table 1. Glypican-3 expression in relation to clinicopathological variables 
  Glypican-3 Score  
  1 2 3 P value 
Age        0.880 
 ≥ 50 14 50.0% 24 48.0% 9 42.9%  
 < 50 14 50.0% 26 52.0% 12 57.1%  
ER status       0.188 
 Negative 21 75.0% 27 54.0% 13 61.9%  
 Positive 7 25.0% 23 46.0% 8 38.1%  
Histologic grading       0.934 
 1 4 14.3% 6 12.0% 3 14.3%  
 2 16 57.1% 30 60.0% 14 66.7%  
 3 8 28.6% 14 28.0% 4 19.0%  
Primary tumor staging       0.926 
 T1 4 14.3% 10 20.0% 5 23.8%  
 T2 18 64.3% 25 50.0% 10 47.6%  
 T3 4 14.3% 9 18.0% 4 19.0%  
 T4 2 7.1% 6 12.0% 2 9.5%  
N status       0.776 
 N0 13 46.4% 24 48.0% 11 52.4%  
 N1 6 21.4% 8 16.0% 4 19.0%  
 N2 7 25.0% 8 16.0% 3 14.3%  
 N3 2 7.1% 10 20.0% 3 14.3%  
TNM stage       0.376 
 I 2 7.1% 7 14.3% 5 23.8%  
 II 15 53.6% 21 42.9% 9 42.9%  
 III 11 39.3% 19 38.8% 5 23.8%  
 IV 0 0.0% 2 4.1% 2 9.5%  
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RESULTS 
There were 28 patients (28%) with a score of 1, 50 
patients (51%) with a score of 2 and 21 patients (21%) 
obtained a score of 3 (Table 1). There was no signifi-
cant relationship between Glypican-3 expression and 
age (p = 0.880), estrogen receptor status (p = 0.188), 
histological grading (p = 0.934), primary tumor stag-
ing (p = 0.926), lymph node status (p = 0.776) or 
TNM staging (p = 0.376, Table 1). 
For survival analyses, the end-point was overall 
survival. The overall five-year survival rates for dif-
ferent categories are listed in Table 2. By multivariate 
analysis, TNM stage was significantly related to the 
overall five-year survival rate (Table 3, p < 0.0001). 
Nevertheless, Glypican-3 expression failed to have 
any significant relationship to the overall five-year 
survival (p = 0.129). 
 
DISCUSSION 
An association between changes in GPC3 expres-
sion and tumor growth has been reported in either 
studies. Down-regulation of GPC3 expression has 
been noted in ovarian, mesothelial and breast cancer 
cell lines [9,10,18]. Therefore, this molecule has been 
considered as a tumor suppressor [19]. In contrast, 
up-regulation of GPC3 expression has been reported 
in hepatocarcinoma and embryonal tumors like neuro-
blastoma and Wilms’ tumor [20-22]. Xiang et al. [23] 
observed that GPC3 expression is silenced in breast 
cancer due, at least in part, to promoter hypermethyla-
tion. Furthermore, they observed that ectopic expres-
sion of GPC3 inhibited cell growth in a significant 
proportion of breast cancer cell lines. The authors [23] 
thus concluded that CPC3 is a negative regulator of 
breast cancer growth. The main pathologic influence 
of cancer is its invasion to the surrounding tissue and 
subsequent metastasis to vital organs, and is regarded 
as the main cause of mortality [26]. The metastatic 
process includes the detachment of cell from the pri-
mary tumor, the intravascular invasion, cell dissemi-
nation in the blood, evasion of the immune response, 
extravasation , adhesion and proliferation at the meta-
static site [25-27]. Peters et al. [28] presented evidence 
that GPC3 expression inhibits invasion and metastasis 
in a syngeneic murine model. These authors attributed 
this response to reduced growth and survival under 
Table 2. Overall 5-year survival rate for each category of breast cancer 
Variable Category 5-y Survival rate (%) p 
Age, year ≥50 63.8 0.171 
 <50 76.7  
TNM stage I 100.0 <0.00001 
 II 91.1  
 III 40.0  
 IV 0  
ER status Negative 63.9 0.025 
 Positive 81.2  
Histologic grading 1 61.5 0.591 
 2 73.3  
 3 69.2  
Glypican-3 1 75.0 0.822 
 2 69.9  
 3 66.7  
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stressful condition, impairment of tumor cell motility 
due to increased cell adhesion and β-catenin expres-
sion; the authors [28] thus concluded their data sup-
ported the idea that GPC3 has a protective role against 
breast cancer progression. However, little is known 
about the relationship between CPC3 expression and 
the well-recognized clinicopathological parameters in 
patients with breast cancer. To the best of our 
knowledge, this study is the first report to evaluate the 
possible effect of the GPC3 expression on the survival 
rate of patients with breast cancer. 
Kononen et al. [29] has reported an array-based 
high-throughput technique that allows for analysis of 
very large numbers of tumors simultaneously, at the 
DNA, RNA, or protein level. As many as 1000 cylin-
drical tissue biopsy specimens from individual tumors 
can be arrayed in a TMA block in parallel fashion with 
minimal damage to the origin blocks [12,29,30]. Com-
pared to immunohistochemical analyses of tissue large 
section, TMA provides a higher level of standardiza-
tions for immunohistochemical staining owning to the 
pretreatment and staining of the tumors under exactly 
the same conditions. Additionally, analysis using large 
sections requires the integration of observations from 
multiple regions of a tissue section. In contrast, mor-
phologic classification and interpretation of immuno-
reactivity in TMA are based on findings within one 
small, highly defined tissue area. The criteria for di-
agnosis are therefore much easier to establish between 
individual samples in the array allowing for compari-
sons between different observers [12,29,30]. 
One major concern about the use of TMA is 
whether these small specimens (diameter 0.6 mm) are 
really representative of their donor tumors. Moch et al. 
[12] emphasized that the TMA approach was designed 
to examine tumor populations and not to survey indi-
vidual tumors. Furthermore, their [12] analysis re-
vealed heterogeneity within tumors but suggested this 
heterogeneity did not influence the identification of 
prognostic parameters. In a series of 553 cases of 
breast cancer, Torhort et al. [31] found the prognostic 
value of estrogen receptor, progesterone receptor and 
p53 was completely reproducible using the TMA 
method. TMA proved to be a reliable tool evaluating 
biomarkers as a prognostic indicator in prostate cancer, 
even though prostate cancer is well-known for its het-
erogeneity [32]. In addition, Lars et al. [33] found that 
tissue microarrays are reliable tools for the clinico-
pathological characterization of lung cancer tissue. 
The results of our study-show that GPC3 expression 
in breast cancer using TMA can be obtained smoothly 
and accurately. To the best of our knowledge, this is 
the first report with long-term follow-up regarding the 
use of TMA to evaluate GPC3 expression in invasive 
breast cancer. In this study, TMA was used to analyze 
Glypican-3 expression in 99 patients with a mean fol-
low-up of 67.9±27.4 months (range, 5-98 months). We 
found there was no significant relationship between 
Glypican-3 and other basic clinicopathological pa-
rameters (Table 1). Using multivariate analysis, we 
observed that Glypican-3 did not have any meaningful 
prognostic value and was not significantly related to 
Table 3. Multivariate analysis for overall 5-year survival rate 
Variable p value OR 95% CI 
Age (age ≧50 vs. <50) 0.685 1.0 0.7 2.8 
TNM stage (I, II, III, IV) <0.0001 10.6 5.0 22.7 
ER status (positive vs. negative) 0.019 0.3 0.1 0.8 
Histologic grading (I, 2, 3) 0.063 1.7 1.0 3.1 
Glypican-3 (1, 2, 3) 0.129 1.5 0.9 2.6 
OR: Odds ratio; CI: confidence interval 
 
 
290 C. H. Tsai et al./JCRP 2(2015) 285-292
the overall five-year survival rate (p = 0.129, Table 3). 
This is probably due to the retrospective nature of the 
study and the relatively small number of patients in 
this study. A prospective study with a larger number of 
patients is warranted for further evaluation and eluci-
dation. 
In summary, the use of immunohistochemical 
staining with TMA was convenient and feasible for 
analysis of Glypican-3 expression status in breast 
cancer. Our preliminary results show that Glypican-3 
expression failed to have any significant prognostic 
value in breast cancer. A larger prospective study may 
be warranted for further evaluation. 
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